Evidence map›Paper›PMID 39851539›Full record

ArticleCells2025

miR-223 and Chromogranin A Affect Inflammatory Immune Cell Activation in Liver Metastasis of Neuroendocrine Neoplasms.

Lukas Geisler, Katharina Detjen, Teresa Hellberg, Marlene Kohlhepp, Carsten Grötzinger, Jana Knorr, Ines Eichhorn, Raphael Mohr, Theresa Holtmann, Bertram Wiedenmann and 3 more

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lukas GeislerDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.ORCID 0000-0001-5394-8004
Katharina DetjenDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Teresa HellbergDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Marlene KohlheppDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Carsten GrötzingerDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.ORCID 0000-0001-9872-3087
Jana KnorrDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Ines EichhornDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Raphael MohrDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.ORCID 0000-0003-2403-4275
Theresa HoltmannDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Bertram WiedenmannDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.ORCID 0000-0002-7890-2552
Frank TackeDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.ORCID 0000-0001-6206-0226
Christoph RoderburgDepartment of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, 40225 Düsseldorf, Germany.
Alexander WreeDepartment of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.ORCID 0000-0002-2968-1335

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine neoplasms (NENs) are a diverse group originating from endocrine cells/their precursors in pancreas, small intestine, or lung. The key serum marker is chromogranin A (CgA). While commonly elevated in patients with NEN, its prognostic value is still under discussion. Secretion/posttranslational proteolytic cleavage of CgA results in multiple bioactive fragments, which are essential regulators of the cardiovascular and immune system. miR-223, regulator of Nrlp3 inflammasome and neutrophil activation, was recently found to have decreased in patients with NEN. We performed flow cytometry of circulating neutrophils in a patient cohort (n = 10) with NEN, microdissection and histology of tumor tissue. Subsequently, in vitro transfections using the well-established human pancreatic NEN cell line (BON), and co-culture experiments with primary macrophages and neutrophils were performed. Serum miR-223 in patients correlated with the expression of the neutrophil activation marker CD15 in circulating cells. Neutrophilic CD62L/CD63 showed good discrimination compared to healthy controls. Immune cell-derived miR-155, miR-193 and miR-223 colocalize with neutrophil in the extra-tumoral tissue alongside Nlrp3-associated caspase-1 activation. miR-223 knockdown in BON decreased the CgA intracellularly, increased in cellular granularity and caspase-1 activation. Plasmin inhibitor a2-aP reverted those effects. Western Blot showed fragmented CgA following miR-223 knockdown, which altered the inflammatory potential of neutrophils. Our data hence provide initial insights into an immunoregulatory mechanism via miR-223 and CgA in NEN cells, as regulation of miR-223 in NEN may affect tumor-associated inflammation.

Indexed as

Chromogranin AInflammationLiver NeoplasmsMicroRNAsNeuroendocrine TumorsAgedCell Line, TumorFemaleHumansMacrophagesMaleMiddle AgedNeutrophil ActivationNeutrophilsChromogranin AMicroRNAsMIR223, humanmiR-223neuroendocrine neoplasmneutrophilNlrp3

Identifiers

PMID39851539
PMCPMC11763622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.